University of Utah
The purpose of this clinical trial is to learn if the study treatment Loncastuximab tesirine and Rituximab is safe and efficient before standard of care chimeric antigen receptor T-cell (CAR-T) therapy in patients with relapsed or refractory large B-cell lymphoma.
Inclusion Criteria: * Subject aged ≥ 18 years. * Intended to receive commercial CD19-directed CAR-T cell therapy (axi-cel and liso-cel). * Need for bridging therapy as deemed clinically necessary by the treating physician. * Relapsed or refractory DLBCL, tFL or PMBCL as defined by the 2016 World Health Organization classification (including patients with DLBCL transformed from indolent lymphoma), or high-grade B-cell lymphoma (HGBL), not otherwise specified, and HGBL with MYC and BCL2 and/or BCL6 rearrangements. --Relapsed (disease that has recurred following a response) or refractory (dis…
Patients will receive Loncastuximab Tesirine intravenously for 1-6 cycles (every 21 days) prior to standard of care CAR-T cell therapy.
Rituximab is administered intravenously for 1-6 cycles (every 21 days) prior to standard of care CAR-T cell therapy.
Arctuva estimate
Actual pay is set by the research site.
Verify or correct the compensation shown for this listing.